KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:开放图源暂不可得 入排置信度 0.98

Ivarmacitinib for the treatment of adults with severe alopecia areata: Results from a phase 3 trial.

Cheng Zhou, Chunjun Yang, Weixin Fan, Jiyuan Wu, Dingquan Yang, Hongzhong Jin, Qinping Yang, Guohong Hu, Nengxing Lin, Xiumin Yang, Jianji Wan, Jianglin Zhang, Liming Wu, Yeqin Dai, Lili Ma, Shanshan Li, Juan Su, Jianfang Sun, Yangfeng Ding, Rong Xiao, Su Zhang, Wenwen Jiang, Lihao Wang, Jianzhong Zhang

J Am Acad Dermatol 94(1) 161-171

PMID40976531
PMCID-
DOI10.1016/j.jaad.2025.09.044
发表日期2025-09-21
入排依据:未发现恶性肿瘤人群证据。
PubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。
摘要

摘要

BACKGROUND: Ivarmacitinib, a selective Janus kinase 1 (JAK1) inhibitor, demonstrated efficacy in a phase 2 trial for moderate-to-severe alopecia areata (AA). OBJECTIVE: To evaluate the efficacy and safety of ivarmacitinib in adults with severe AA (≥50% scalp hair loss, including alopecia totalis/universalis). METHODS: In this randomized, double-blind, phase 3 trial, 330 patients were assigned (1:1:1) to ivarmacitinib 4 mg, 8 mg, or placebo once daily for 24 weeks. Placebo recipients were re-randomized to ivarmacitinib for a 28-week extension. The primary endpoint was the proportion achieving a Severity of Alopecia Tool (SALT) score ≤20 at week 24. RESULTS: At week 24, SALT ≤20 was achieved by 34.9% (4 mg), 40.6% (8 mg), and 9.0% (placebo). Absolute differences versus placebo were 25.6% (95% CI: 15.4-35.7) for 4 mg and 31.6% (21.5-41.8) for 8 mg (both P < .0001). Treatment-emergent adverse events occurred in 77.1%, 84.7%, and 75.5% of patients, respectively; most were mild or moderate. No deaths, major cardiovascular events, or thromboembolic events were reported. LIMITATION: No active comparator was used. CONCLUSION: Once-daily ivarmacitinib 4 mg or 8 mg resulted in meaningful hair regrowth and demonstrated an acceptable safety profile in patients with severe AA.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。